Vimarsana
Biggest News Aggregation in the World

Michael Meo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Meo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Meo Today - Breaking & Trending Today

WOIO Cleveland 19 News At 6PM September 9, 2016 - Vimarsana News

WOIO Cleveland 19 News At 6PM September 9, 2016

They will only get sober one way, dying. Rhonda says how pathetic. Let the adult do what they want to their lives but keep the child safe and away from them. How sad we have to worry about people driving while o. D. Ing and another comment. Beth says it is not a personal crisis it is a community crisis. That baby has been exposed by junkies in the car not by the media. I dont think it is fair they are using and under the influencil many innocent lives and especially a school bus full of children. It is not fair. There was a school bus in the area with kids when the car rolled to a stop because...

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - Vimarsana News

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%...

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - Vimarsana News

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria - Vimarsana News

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® to account for metabolic differences in babies under 5...